ArticlePLoS pathogens2026
Lumpy skin disease virus protein LSDV122 impairs IFN-I receptor complex formation to evade host innate immunity.
Article in PLoS pathogens, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lumpy skin disease virus (LSDV) is a pathogenic poxvirus that causes systemic disease in cattle. Although LSDV encodes multiple proteins that are predicted to regulate host defense, the underlying mechanisms of its immune evasion strategies remain largely elusive. Here we identify the LSDV-encoded protein LSDV122 as an antagonist of type I interferon (IFN-I)-mediated innate immunity. LSDV122 interacts with both subunits of the IFN-I receptor, IFNAR1 and IFNAR2, disrupting their proper assembly and preventing the recruitment of the downstream kinases JAK1 and TYK2, leading to impairment of IFN-β-mediated JAK-STAT signaling and induction of antiviral IFN-stimulated genes (ISGs). Deletion of the LSDV122 gene (LSDVΔ122) led to stronger antiviral response by restoring IFN-β-induced signaling in vitro and in a mouse model. Our study suggests that LSDV122 plays a critical role in antagonizing IFN-I signaling and is essential for efficient viral immune evasion, offering new insights into the rational design of live-attenuated LSDV vaccines.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.